YUSIMRY
PeakmAbadalimumab-aqvh
BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
YUSIMRY (adalimumab-aqvh) is tumor necrosis factor receptor blocking activity [moa]. First approved in 2021.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUSIMRY (adalimumab-aqvh) is a monoclonal antibody TNF receptor blocker approved in December 2021 for 12 immunoinflammatory indications ranging from rheumatoid arthritis to hidradenitis suppurativa. It works by binding and neutralizing tumor necrosis factor, a key driver of chronic inflammation. This is a biosimilar referencing the originator adalimumab (Humira), entering a mature, competitive TNF-inhibitor market.
Peak
Product is in peak lifecycle phase as a newer biosimilar entrant; commercial teams are focused on market penetration and payer negotiations to gain formulary position against established TNF inhibitors.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on YUSIMRY offers exposure to a mature biosimilar launch navigating intense payer and competitive pressure in a crowded TNF-inhibitor market. Roles emphasize payer negotiations, competitive differentiation on price/access, and field execution in a growth-challenged environment with high sales turnover risk.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.